Abstract
PARPi are indicated as maintenance therapy after 1st line chemotherapy, for patients (pts) with high-grade ovarian cancer (HGOC) in case of BRCA mutation, high genomic instability score (GIS), or objective response to platinum. Herein, GIS is required straight away, for all pts with HGOC to select the best maintenance strategy between bevacizumab, PARPi or both combined. Around 10% of HGOC are platinum-refractory with progressive disease during or within 4 weeks of last platinum, and additional 10% present no objective response (OR-) to platinum, and both are not eligible for PARPi.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
